José Carlos Subtil Íñigo-rekin lankidetzan egindako argitalpenak (8)

2023

  1. Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma

    Pancreatology, Vol. 23, Núm. 4, pp. 411-419

2019

  1. Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling

    PLoS ONE, Vol. 14, Núm. 5

  2. Use of machine-learning algorithms in intensified preoperative therapy of pancreatic cancer to predict individual risk of relapse

    Cancers, Vol. 11, Núm. 5

2018

  1. Intensified neoadjuvant multimodal approach in synchronous liver metastases from gastric cancer: a single institutional experience

    Clinical and Translational Oncology, Vol. 20, Núm. 5, pp. 658-665

2016

  1. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer

    British Journal of Cancer, Vol. 115, Núm. 6, pp. 655-663

2012

  1. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: A validation phase II trial

    International Journal of Radiation Oncology Biology Physics, Vol. 83, Núm. 2, pp. 587-593

2011

  1. Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: Can we trust the findings?

    Diseases of the Colon and Rectum, Vol. 54, Núm. 9, pp. 1141-1146

  2. Patterns of response after preoperative intensity-modulated radiation therapy and capecitabine/oxaliplatin in rectal cancer: Is there still a place for ecoendoscopic ultrasound?

    International Journal of Radiation Oncology Biology Physics, Vol. 81, Núm. 2, pp. 439-444